{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:47:59Z","timestamp":1781938079826,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["07330462210007"],"award-info":[{"award-number":["07330462210007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["07330462210007"],"award-info":[{"award-number":["07330462210007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003607","name":"Association for Frontotemporal Degeneration","doi-asserted-by":"publisher","award":["2024-005"],"award-info":[{"award-number":["2024-005"]}],"id":[{"id":"10.13039\/100003607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003607","name":"Association for Frontotemporal Degeneration","doi-asserted-by":"publisher","award":["2024-005"],"award-info":[{"award-number":["2024-005"]}],"id":[{"id":"10.13039\/100003607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022722","name":"GIESKES-STRIJBIS FONDS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["WE.09-2022-05"],"award-info":[{"award-number":["WE.09-2022-05"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["WE.09-2022-05"],"award-info":[{"award-number":["WE.09-2022-05"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As understanding of biomarkers for genetic frontotemporal dementia (FTD) advances, there is a need to develop onset-predictive biomarker tests (OPBTs) to detect changes before the onset of symptoms. OPBTs can be used to recruit carriers or individuals at 50% risk of carriership into clinical trials of investigational therapies targeting the preclinical and prodromal phases of FTD. OPBT results should be disclosed as part of the informed consent process, with positive results indicating that symptom onset is likely in the next few years. This information can be psychologically burdensome, especially in individuals at 50% risk, for whom a positive OPBT result would reveal their genetic status. There is a need for ethical guidance for disclosure processes to help researchers implement disclosure of OPBT results responsibly at their study sites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Existing literature on disclosure of genetic and biomarker results in neurodegenerative conditions informed the design of this disclosure process for OPBT in FTD. Drafts were discussed with the multidisciplinary research team, scientific and clinical FTD experts across European countries, and other stakeholders and revised accordingly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The suggested disclosure process provides guidance for first-time or repeated disclosure of OPBT results to carriers or individuals at 50% risk of genetic FTD in research settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Researchers involved in clinical trials using OPBTs can adopt this disclosure process as a framework for responsible communication of OPBT results at their study site. The process was designed for international applicability and facilitates the alignment of disclosure processes for clinical trial recruitment across European countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01930-4","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T09:23:39Z","timestamp":1765617819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disclosure of onset-predictive biomarker results to research participants at risk of genetic frontotemporal dementia: a European perspective"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2178-0032","authenticated-orcid":false,"given":"Charlotte H.","family":"Graafland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1481-6222","authenticated-orcid":false,"given":"Eline M.","family":"Bunnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-9814","authenticated-orcid":false,"given":"Barbara","family":"Borroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0267-8590","authenticated-orcid":false,"given":"Arabella","family":"Bouzigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2557-0010","authenticated-orcid":false,"given":"Sergi","family":"Borrego-\u00c9cija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-9524","authenticated-orcid":false,"given":"Eino","family":"Solje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9949-2951","authenticated-orcid":false,"given":"Caroline","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6155-8417","authenticated-orcid":false,"given":"Jonathan D.","family":"Rohrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6278-6844","authenticated-orcid":false,"given":"John C.","family":"van Swieten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2436-0931","authenticated-orcid":false,"given":"Laura","family":"Donker Kaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-7527","authenticated-orcid":false,"given":"Harro","family":"Seelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"issue":"5","key":"1930_CR1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/jnnp.2010.212225","volume":"82","author":"H Seelaar","year":"2011","unstructured":"Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82(5):476\u201386. https:\/\/doi.org\/10.1136\/jnnp.2010.212225.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1930_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41572-023-00447-0","volume":"9","author":"M Grossman","year":"2023","unstructured":"Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. https:\/\/doi.org\/10.1038\/s41572-023-00447-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"1930_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/WCO.0000000000001174","volume":"36","author":"LL Russell","year":"2023","unstructured":"Russell LL, Rohrer JD. Defining the presymptomatic phase of frontotemporal dementia. Curr Opin Neurol. 2023;36(4):276\u201382. https:\/\/doi.org\/10.1097\/WCO.0000000000001174.","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"1930_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11910-016-0707-9","volume":"16","author":"DA Olszewska","year":"2016","unstructured":"Olszewska DA, Lonergan R, Fallon EM, Lynch T. Genetics of frontotemporal dementia. Curr Neurol Neurosci Rep. 2016;16(12):107. https:\/\/doi.org\/10.1007\/s11910-016-0707-9.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"1930_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(19)30394-1","volume":"19","author":"KM Moore","year":"2020","unstructured":"Moore KM, Nicholas J, Grossman M, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 2020;19(2):145\u201356. https:\/\/doi.org\/10.1016\/S1474-4422(19)30394-1.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1930_CR6","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/s41591-022-01942-9","volume":"28","author":"AM Staffaroni","year":"2022","unstructured":"Staffaroni AM, Quintana M, Wendelberger B, et al. Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nat Med. 2022;28(10):2194\u2013206. https:\/\/doi.org\/10.1038\/s41591-022-01942-9.","journal-title":"Nat Med"},{"issue":"10","key":"1930_CR7","doi-asserted-by":"publisher","first-page":"e1069","DOI":"10.1212\/WNL.0000000000207581","volume":"101","author":"LAA Giannini","year":"2023","unstructured":"Giannini LAA, Seelaar H, van der Ende EL, et al. Clinical value of longitudinal serum neurofilament light chain in prodromal genetic frontotemporal dementia. Neurology. 2023;101(10):e1069\u201382. https:\/\/doi.org\/10.1212\/WNL.0000000000207581.","journal-title":"Neurology"},{"issue":"1","key":"1930_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/ana.26265","volume":"91","author":"C Wilke","year":"2022","unstructured":"Wilke C, Reich S, van Swieten JC, et al. Stratifying the presymptomatic phase of genetic frontotemporal dementia by serum NfL and pNfH: a longitudinal multicentre study. Ann Neurol. 2022;91(1):33\u201347. https:\/\/doi.org\/10.1002\/ana.26265.","journal-title":"Ann Neurol"},{"key":"1930_CR9","unstructured":"Alector Inc. (2023) A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04374136.\u00a0Accessed 1 Jan 2023."},{"issue":"2","key":"1930_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70133","volume":"17","author":"CH Graafland","year":"2025","unstructured":"Graafland CH, Donker Kaat LD, Richard E, et al. Ethics of disclosure of onset-predictive biomarker test results for genetic frontotemporal dementia in the research context. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2025;17(2):e70133. https:\/\/doi.org\/10.1002\/dad2.70133.","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"1930_CR11","volume-title":"Genetic testing protocol for huntington\u2019s disease","author":"Huntington\u2019s Disease Society of America (HDSA)","year":"2016","unstructured":"Huntington\u2019s Disease Society of America (HDSA). Genetic testing protocol for huntington\u2019s disease. New York: HDSA; 2016."},{"issue":"3","key":"1930_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1399-0004.2012.01900.x","volume":"83","author":"R MacLeod","year":"2013","unstructured":"MacLeod R, Tibben A, Frontali M, et al. Recommendations for the predictive genetic test in Huntington\u2019s disease. Clin Genet. 2013;83(3):221\u201331. https:\/\/doi.org\/10.1111\/j.1399-0004.2012.01900.x.","journal-title":"Clin Genet"},{"issue":"24","key":"1930_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1212\/WNL.0000000000002773","volume":"86","author":"M Benatar","year":"2016","unstructured":"Benatar M, Stanislaw C, Reyes E, et al. Presymptomatic ALS genetic counseling and testing: experience and recommendations. Neurology. 2016;86(24):2295\u2013302. https:\/\/doi.org\/10.1212\/WNL.0000000000002773.","journal-title":"Neurology"},{"issue":"4","key":"1930_CR14","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","volume":"19","author":"M Benatar","year":"2022","unstructured":"Benatar M, Wuu J, Andersen PM, et al. Design of a randomized, placebo-controlled, phase 3 trial of Tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics. 2022;19(4):1248\u201358. https:\/\/doi.org\/10.1007\/s13311-022-01237-4.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1930_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/gim.2017.103","volume":"20","author":"KD Christensen","year":"2018","unstructured":"Christensen KD, Uhlmann WR, Roberts JS, et al. A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med. 2018;20(1):132\u201341. https:\/\/doi.org\/10.1038\/gim.2017.103.","journal-title":"Genet Med"},{"issue":"1","key":"1930_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-015-0112-7","volume":"7","author":"K Harkins","year":"2015","unstructured":"Harkins K, Sankar P, Sperling R, et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7(1):26. https:\/\/doi.org\/10.1186\/s13195-015-0112-7.","journal-title":"Alzheimers Res Ther"},{"key":"1930_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.trci.2019.09.013","volume":"5","author":"CM Langlois","year":"2019","unstructured":"Langlois CM, Bradbury A, Wood EM, et al. Alzheimer\u2019s prevention initiative generation program: development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2019;5:705\u201316. https:\/\/doi.org\/10.1016\/j.trci.2019.09.013.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"1","key":"1930_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/JAD-150985","volume":"52","author":"JH Lingler","year":"2016","unstructured":"Lingler JH, Butters MA, Gentry AL, et al. Development of a standardized approach to disclosing amyloid imaging research results in mild cognitive impairment. J Alzheimers Dis. 2016;52(1):17\u201324. https:\/\/doi.org\/10.3233\/JAD-150985.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"1930_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/gim.2012.37","volume":"14","author":"JS Roberts","year":"2012","unstructured":"Roberts JS, Chen CA, Uhlmann WR, Green RC. Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for alzheimer disease. Genet Med. 2012;14(8):742\u20138. https:\/\/doi.org\/10.1038\/gim.2012.37.","journal-title":"Genet Med"},{"issue":"21","key":"1930_CR20","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1212\/WNL.0000000000206891","volume":"100","author":"EA Largent","year":"2023","unstructured":"Largent EA, Grill JD, O\u2019Brien K, Wolk D, Harkins K, Karlawish J. Testing for alzheimer disease biomarkers and disclosing results across the disease continuum. Neurology. 2023;100(21):1010\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000206891.","journal-title":"Neurology"},{"issue":"3","key":"1930_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3233\/JAD-230359","volume":"97","author":"JM Robillard","year":"2024","unstructured":"Robillard JM, Masellis M, Martin SE, Khachaturian AS, Dixon RA. The return of biomarker results in research: balancing complexity, precision, and ethical responsibility. J Alzheimers Dis. 2024;97(3):1083\u201390. https:\/\/doi.org\/10.3233\/JAD-230359.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1930_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-025-01749-z","volume":"17","author":"CH Graafland","year":"2025","unstructured":"Graafland CH, Seelaar H, Panman JL, et al. \u201cIt seems enormously valuable to me.\u201d Perspectives of Dutch (potential) carriers of genetic FTD on onset-predictive biomarker testing. Alzheimers Res Ther. 2025;17:99. https:\/\/doi.org\/10.1186\/s13195-025-01749-z.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"1930_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/gim.2014.134","volume":"17","author":"AR Bradbury","year":"2015","unstructured":"Bradbury AR, Patrick-Miller L, Long J, et al. Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med. 2015;17(6):485\u201392. https:\/\/doi.org\/10.1038\/gim.2014.134.","journal-title":"Genet Med"},{"issue":"2","key":"1930_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.14283\/jpad.2017.5","volume":"4","author":"R Milne","year":"2017","unstructured":"Milne R, Bunnik E, Tromp K, et al. Ethical issues in the development of readiness cohorts in alzheimer\u2019s disease research. J Prev Alzheimers Dis. 2017;4(2):125\u201331. https:\/\/doi.org\/10.14283\/jpad.2017.5.","journal-title":"J Prev Alzheimers Dis"},{"issue":"7\u20138","key":"1930_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/21678421.2017.1332079","volume":"18","author":"A Crook","year":"2017","unstructured":"Crook A, Williams K, Adams L, Blair I, Rowe DB. Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7\u20138):475\u201385. https:\/\/doi.org\/10.1080\/21678421.2017.1332079.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1930_CR26","unstructured":"Graafland CH, Seelaar H, Panman JL et al. Reasons for and against presymptomatic genetic testing in frontotemporal dementia: a qualitative study. Human Genet. In press."},{"issue":"12","key":"1930_CR27","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/jnnp-2021-326914","volume":"92","author":"D Saracino","year":"2021","unstructured":"Saracino D, Dorgham K, Camuzat A, et al. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. J Neurol Neurosurg Psychiatry. 2021;92(12):1278\u201388. https:\/\/doi.org\/10.1136\/jnnp-2021-326914.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"14","key":"1930_CR28","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1212\/WNL.0000000000001451","volume":"84","author":"SY Kim","year":"2015","unstructured":"Kim SY, Karlawish J, Berkman BE. Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology. 2015;84(14):1488\u201394. https:\/\/doi.org\/10.1212\/WNL.0000000000001451.","journal-title":"Neurology"},{"issue":"9","key":"1930_CR29","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1017\/S1041610211001013","volume":"23","author":"D van Vliet","year":"2011","unstructured":"van Vliet D, de Vugt ME, Bakker C, et al. Caregivers\u2019 perspectives on the pre-diagnostic period in early onset dementia: a long and winding road. Int Psychogeriatr. 2011;23(9):1393\u2013404. https:\/\/doi.org\/10.1017\/S1041610211001013.","journal-title":"Int Psychogeriatr"},{"key":"1930_CR30","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.20240238","author":"ER Mukwikwi","year":"2025","unstructured":"Mukwikwi ER, Jones SL, Manera AL, et al. Prevalence and features of misdiagnosis of primary psychiatric disorders among BvFTD patients. J Neuropsychiatry Clin Neurosci. 2025. https:\/\/doi.org\/10.1176\/appi.neuropsych.20240238. Published online April 28, 2025.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"7","key":"1930_CR31","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/alz.12485","volume":"18","author":"A Benussi","year":"2022","unstructured":"Benussi A, Alberici A, Samra K, et al. Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimers Dement. 2022;18(7):1408\u201323. https:\/\/doi.org\/10.1002\/alz.12485.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1930_CR32","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/brain\/awab365","volume":"145","author":"MS Barker","year":"2022","unstructured":"Barker MS, Gottesman RT, Manoochehri M, et al. Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain. 2022;145(3):1079\u201397. https:\/\/doi.org\/10.1093\/brain\/awab365.","journal-title":"Brain"},{"issue":"6","key":"1930_CR33","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41582-024-00961-z","volume":"20","author":"M Benatar","year":"2024","unstructured":"Benatar M, Wuu J, Huey ED, et al. The Miami framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology. Nat Rev Neurol. 2024;20(6):364\u201376. https:\/\/doi.org\/10.1038\/s41582-024-00961-z.","journal-title":"Nat Rev Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01930-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01930-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01930-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:29:38Z","timestamp":1768850978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01930-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1930"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01930-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E. Solje has served on the advisory board of Novartis, EISAI, Lilly and Roche, served as a consult for Novo Nordisk, BioaArctic, EISAI, Lilly and Roche and received honoraria from for lectures from Lundbeck, BioaArctic and Roche and travel support from Lilly. Other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}